European Union Approves Novavax Coronavirus Vaccine

Video Credit: Wibbitz Top Stories
Published on December 21, 2021 - Duration: 01:31s

European Union Approves Novavax Coronavirus Vaccine

European Union Approves , Novavax Coronavirus Vaccine.

ABC News reports the European Union has authorized the use of the Novavax COVID-19 vaccine.

Manufactured in the United States, Novavax's two-dose vaccine will be the fifth coronavirus vaccine approved by the European Union.

Manufactured in the United States, Novavax's two-dose vaccine will be the fifth coronavirus vaccine approved by the European Union.

According to ABC News, the European Union has ordered around 100 million doses of the Novavax vaccine.

Research conducted by the European Medicines Agency shows "the data on the vaccine were robust and met the EU criteria for efficacy, safety, and quality.โ€ .

The Novavax vaccine is protein-based, a technique long used in vaccine production.

.

In a study of 30,000 citizens of the United States and Mexico, the vaccine was proven safe and 90% effective against earlier variants of the coronavirus.

In a study of 30,000 citizens of the United States and Mexico, the vaccine was proven safe and 90% effective against earlier variants of the coronavirus.

The Novavax vaccine only requires refrigeration to remain effective.

Experts say this trait could minimize the impact of global vaccine inequity.

Novavax CEO Stanley C.

Erck said the decision would โ€œdeliver the vaccine to the E.U.

During a critical time when we believe having choice among vaccines will lead to increased immunization.โ€.

Novavax CEO Stanley C.

Erck said the decision would โ€œdeliver the vaccine to the E.U.

During a critical time when we believe having choice among vaccines will lead to increased immunization.โ€


You are here


๐Ÿ’ก newsR Knowledge: Other News Mentions


COVID-19

Contagious disease caused by SARS-CoV-2
Monkeypox may be less transmittable than COVID, but the virus is exploding and most folks aren't immune to its effects ... so says, Dr. Eric Feigl-Ding. The..
Credit: TMZ.com - Published 7 hours ago

The US Food and Drug Administration (USFDA) has lifted the clinical hold on the Phase 2 and 3 immuno-bridging clinical trials of Bharat Biotechโ€™s Covid-19..
Credit: IndiaTimes - Published 14 hours ago

Monkeypox is a "particularly nasty virus" and it is "important we get it under control" - but it only poses a "very low" threat to the wider public and is not..
20 hours ago • Sky News

You might like